Skip to main content
Premium Trial:

Request an Annual Quote

Burnham Institute, PHRI, UMich, and Brandeis and Brigham Women's Execute Licensing Deals

Premium
Following is a summary of recent notable licensing deals executed by academic or non-profit research institutions in biotechnology and life sciences.
 
 
Institution: Burnham Institute for Medical Research
 
Primary Inventors: Erkki Ruoslahti, professor and former president of Burnham Institute; and Masanobu Komatsu, assistant professor at University of Alabama-Birmingham School of Medicine and former postdoctoral fellow at Burnham
 
Licensee: Vascular Biosciences, San Diego
 
Technology: Intellectual property related to the role of the intracellular protein R-Ras in neointimal hyperplasia, angiogenesis, and vascular proliferation. Ruoslahti and Komatsu found that R-Ras exerts a strong inhibitory effect on mitotic and invasive activities of activated endothelial cells and vascular smooth muscle cells, and promotes quiescence of these cells. Vascular Biosciences is targeting R-Ras signaling to develop therapies for a wide range of disorders.
 

 
Institution: Public Health Research Institute Center, an extension of UMDNJ-New Jersey Medical School
 
Primary Inventors: Fred Kramer, member and chairman, PHRI, and research professor at the New York University School of Medicine; and Sanjay Tyagi, principal investigator, PHRI
 
Licensee: Applied DNA Sciences, Stony Brook, NY
 
Technology: Fluorescent single-stranded oligonucleotide hybridization “molecular beacon” probes. Applied DNA Sciences will incorporate the molecular beacons in next-generation detection devices for use in ID verification, forensics, and other applications.
 

 
Institution: University of Michigan
 
Primary Inventor: David Kurnit, professor of pediatrics and communicable diseases, University of Michigan Medical Center
 
Licensee: SensiGen, Ann Arbor, Mich.
 
Technology: Ultra-sensitive human papillomavirus detection test based on the detection of HPV DNA in blood or tissue samples, and able to identify unique genotypes of the disease that cause cervical cancer. SensiGen will market the test under the name AttoSense.
 

 
Institutions: Brandeis University and Brigham and Women’s Hospital
 
Primary Inventors: Raquel Lieberman, research fellow, neurology, Brigham and Women’s Hopsital; Gregory Petsko, faculty, Brandeis University, and visiting professor, neurology, Brigham and Women’s; and Dadgmar Ringe, faculty, Brandeis, and visiting professor, neurology, Brigham and Women’s
 
Licensee: Amicus Therapeutics
 
Technology: Intellectual property related to the structure of β-glucosidase, also known as GCase. In collaboration with Amicus, the researchers discovered that GCase, which is mutated in Gaucher disease, undergoes a structural change near its active site upon binding to a small molecule. Amicus is currently testing the small molecule in clinical trials for treatment of the disease.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.